DBV Technologies盘前大涨超30%。消息上,DBV Technologies宣布了VIASKIN花生贴片在4-7岁花生过敏儿童中的3期VITESSE试验取得了积极的初步结果,达到了其主要终点。针对4-7岁儿童的BLA提交按计划将在2026年上半年进行。
美股频道更多独家策划、专家专栏,免费查阅>>
DBV Technologies盘前大涨超30%。消息上,DBV Technologies宣布了VIASKIN花生贴片在4-7岁花生过敏儿童中的3期VITESSE试验取得了积极的初步结果,达到了其主要终点。针对4-7岁儿童的BLA提交按计划将在2026年上半年进行。
美股频道更多独家策划、专家专栏,免费查阅>>
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.